Risks of suicide and poisoning among elderly patients prescribed selective serotonin reuptake inhibitors: A retrospective cohort study

Journal of Clinical Psychiatry

Volumn 69, Issue 3, 2008, Pages 349-357

  Rahme, Elham ^a,b   Dasgupta, Kaberi ^a,b   Turecki, Gustavo ^a,c   Nedjar, Hacene ^b   Galbaud Du Fort, Guillaume ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM CARBONATE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NALTREXONE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; INTOXICATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SUICIDE;

EID: 42249093010     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0303     Document Type: Article

References (32)

1. Isacsson G, Bergman U, Rich CL. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Disord 1996;41:1-8
2. Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry 2004;4:37
3. Oquendo MA, Malone KM, Ellis SP, et al. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. Am J Psychiatry 1999;156:190-194
4. Juurlink DN, Mamdani MM, Kopp A, et al. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006;163:813-821
5. Leon AC, Marzuk PM, Tardiff K, et al. Antidepressants and youth suicide in New York City, 1999-2002. J Am Acad Child Adolesc Psychiatry 2006;45:1054-1058
6. Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005;111:286-290
7. Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003;160:790-792
8. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005;330:396
9. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330:385
10. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292:338-343
11. Simon GE, Savarino J, Operskalski B, et al. Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163:41-47
12. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210
13. Center for Drug Evaluation and Research. Worsening depression and suicidality in patients being treated with antidepressant medications [US Food and Drug Administration (FDA) Web site]. March 22, 2004. Available at http://www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.htm. Accessed Sept 7, 2005
14. Committee on Safety of Medicines. Medicines and Healthcare products Regulatory Agency, United Kingdom. Use of selective serotonin reuptake inhibitors (SSRIs) in children and adolescents with major depressive disorder (MDD)-only fluoxetine (Prozac) shown to have a favorable balance of risks and benefits for the treatment of MDD in the under 18s. United Kingdom, 2003. Available at http://www.mhra.gov.uk/home/idcplg?IdcService= SS_GET_Page&ssDocName= CON019494&ssSourceNodeId=242&ssTargetNodeId= 221. Accessed Sept 7, 2005
15. Health Canada. Health Canada advises Canadians of stronger warnings for SSRIs and other newer anti-depressants. Canada; 2004. Available at http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2004/2004_31_e.html. Accessibility verified Sept 21, 2007
16. Canada Rx Report 2005. [Announcement posted on the World Wide Web]. Available at: http://www.imshealthcanada.com/vgn/images/portal/cit_40000873/51/ 30/78610823FINAL_Canada_RX_Report_english.pdf. Accessibility verified Oct 23, 2007
17. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006;63:1358-1367
18. Public Health Agency of Canada. Inventory of Injury Data Sources and Surveillance Activities. Centre for Surveillance Coordination. Ottawa, Ontario, Canada: Public Health Agency of Canada; 2005
19. Moride Y, Galbaud du Fort G, Monette J, et al. Suboptimal duration of antidepressant treatments in the older ambulatory population of Quebec: association with selected physician characteristics. J Am Geriatr Soc 2002;50:1365-1371
20. Hawton K, Harriss L. Deliberate self-harm in people aged 60 years and over: characteristics and outcome of a 20-year cohort. Int J Geriatr Psychiatry 2006;21:572-581
21. Ake CF, Carpenter AL. Extending the use of PROC PHREG in survival analysis. 2003. Available at http://www.caloxy.com/papers/51-ExtendingPHREG.pdf. Accessibility verified Oct 16, 2007
22. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder [Revision]. Am J Psychiatry 2000;157(suppl 4):1-45
23. Reynolds CF 3rd, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999;281:39-45
24. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-362
25. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br J Psychiatry 2000;176:363-368
26. Isacsson G, Boethius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand 1992;85:444-448
27. Isacsson G, Holmgren P, Druid H, et al. The utilization of antidepressants - a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994. Acta Psychiatr Scand 1997;96:94-100
28. Callahan CM, Hendrie HC, Nienaber NA, et al. Suicidal ideation among older primary care patients. J Am Geriatr Soc 1996;44:1205-1209
29. Carlsten A, Waern M, Holmgren P, et al. The role of benzodiazepines in elderly suicides. Scand J Public Health 2003;31:224-228
30. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990;81:185-189
31. Rubino A, Roskell N, Tennis P, et al. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334:242
32. Institut national de santé publique du Québec. L'épidémiologie du suicide au Québec: que savons-nous de la situation récente? Quebec, Canada, 2004. Available at http://www.inspq.qc.ca/pdf/publications/281-EpidemiologieSuicide.pdf. Accessed Feb 24, 2006